The coincident antigen-specific upregulation of FAS/FASL and PD-1/PD-L2 on T cells and CAFs, respectively, drives the death and dysfunction of tumor-specific T cells, resulting in enhanced tumor viability (71). Here, PDCD1LG2 is linked to neoplasm.